Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CorMedix Inc.CRMD · Entity 5280 | EVP, Chief Commercial Officer | February 18, 2022 | February 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CorMedix Inc.
Report date February 18, 2022 · Filed February 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2032-02-18 | Direct | 100,000 |
Reported balance
After 2022-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-18 · Grant · Acquired 100,000 · Balance 100,000 F1: These options were granted on 02/18/2022. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $7.56 · Expires 2031-05-13 | Direct | 260,000 |
Reported balance
Holding disclosure · report date 2022-02-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 260,000 F2: The options vest as follows: 160,000 will vest over four years in four (4) equal installments on the first four anniversaries of May 13, 2021. The remaining 100,000 options vest on the achievement of certain milestones, subject to continued employment. |
| Stock Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $7.56 · Expires 2031-05-13 | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2022-02-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 7,500 F3: These options were granted on May 13, 2021. These options shall vest in full on the first anniversary of the grant date, subject to continued employment. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted on 02/18/2022. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.
F2: The options vest as follows: 160,000 will vest over four years in four (4) equal installments on the first four anniversaries of May 13, 2021. The remaining 100,000 options vest on the achievement of certain milestones, subject to continued employment.
F3: These options were granted on May 13, 2021. These options shall vest in full on the first anniversary of the grant date, subject to continued employment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2022 Filed Feb 23, 2022 16:14 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 100,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0001213900-22-008943 · doc4.xml · derivative · entry 1 Nusbickel Thomas · CIK 0001863281 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-18 F1 · derivative.exercise_date: These options were granted on 02/18/2022. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| May 13, 2021 Filed May 20, 2021 16:18 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 7,500 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001213900-21-028172 · ownership.xml · derivative · entry 2 Nusbickel Thomas · CIK 0001863281 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-05-13 F2 · derivative.exercise_date: These options were granted on May 13, 2021. These options shall vest in full on the first anniversary of the grant date, subject to continued employment. Read SEC document |
| May 13, 2021 Filed May 20, 2021 16:18 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantStock Option (Right to Buy Common Stock) · Derivative | 260,000 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001213900-21-028172 · ownership.xml · derivative · entry 1 Nusbickel Thomas · CIK 0001863281 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: The options vest as follows: 160,000 will vest over four years in four (4) equal installments on the first four anniversaries of May 13, 2021. The remaining 100,000 options vest on the achievement of certain milestones, subject to continued employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.